Table 1. Clinicopathological characteristics and univariate analysis of recurrence-free survival (RFS) in patients who received adjuvant gemcitabine chemotherapy after curative resection for BTC.
| Variables | N (event) | Univariable (RFS) | |
|---|---|---|---|
| HR (95% CI) | p value | ||
| Age | 72 (44) | 1.01 (0.97–1.04) | 0.656 |
| Gender | |||
| Female | 24 (16) | 1 | |
| Male | 48 (28) | 0.79 (0.43–1.46) | 0.455 |
| Gross type | |||
| Extrahepatic cholangiocarcinoma | 33 (20) | 1 | 0.253 |
| GB cancer | 26 (14) | 0.98 (0.50–1.94) | 0.957 |
| Intrahepatic cholangiocarcinoma | 13 (10) | 1.81 (0.84–3.87) | 0.128 |
| Differentiation | |||
| Well differentiated | 18 (9) | 1 | 0.166 |
| Moderately differentiated | 27 (17) | 1.36 (0.61–3.05) | 0.457 |
| Poorly differentiated | 20 (15) | 2.24 (0.98–5.13) | 0.057 |
| Other | 7 (3) | 0.82 (0.22–3.03) | 0.765 |
| Tumor size (cm) | 72 (44) | 1.06 (0.91–1.23) | 0.470 |
| Vascular invasion | |||
| Absent | 47 (23) | 1 | |
| Present | 25 (21) | 3.27 (1.77–6.01) | < .001 |
| Perineural invasion | |||
| Absent | 21 (8) | 1 | |
| Present | 51 (36) | 2.15 (1.00–4.66) | 0.052 |
| Lymphatic invasion | |||
| Absent | 25 (10) | 1 | |
| Present | 47 (34) | 2.81 (1.38–5.72) | 0.004 |
| T stage | |||
| T1 + T2 | 43 (22) | 1 | |
| T3 + T4 | 29 (22) | 2.07 (1.14–3.76) | 0.017 |
| N stage | |||
| N0 | 40 (18) | 1 | |
| N1 | 32 (26) | 3.35 (1.81–6.20) | < .001 |
| ECOG performance status | |||
| 0 | 19 (12) | 1 | |
| 1 | 53 (32) | 0.71 (0.37–1.38) | 0.312 |
| Gemcitabine dosage | 72 (44) | 0.998 (0.996–1.000) | 0.030 |
| hENT1 (miss = 6) | |||
| Negative | 35 (26) | 1 | |
| Postive | 31 (17) | 0.71 (0.38–1.31) | 0.267 |
| dCK (miss = 6) | |||
| Negative | 45 (32) | 1 | |
| Postive | 21 (11) | 0.61 (0.31–1.22) | 0.160 |
| CDA (miss = 6) | |||
| Negative | 28 (17) | 1 | |
| Postive | 38 (26) | 1.43 (0.78–2.64) | 0.251 |
| RRM1 (miss = 6) | |||
| Negative | 24 (15) | 1 | |
| Postive | 42 (28) | 1.24 (0.66–2.32) | 0.505 |